1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €9.45 (+52.67%). The median is €6.02 (-2.75%).
| Buy |
2 |
| Hold |
5 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | March 2026 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -4.97M | 67.51% |
| EBITDA | 40.6K | 100.28% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €46.29M |
Number of shares | 7.39M |
52-week high/low | €6.49 - €3.03 |
| Dividends | No |
Beta | 0.41 |
P/E ratio | -1.18 |
PEG ratio | 0.05 |
P/B ratio | 0.82 |
P/S ratio | 0.00 |
Company profile
| Name | Kezar Life Sciences Aktie |
| CEO | Christopher J. Kirk |
| Employees | 55 |
Discover assets
Shareholders of Kezar Life Sciences Aktie also invest in the following assets
